After being recently approved in Europe, a biosimilar for the drug rituximab (MabThera in Europe) could result in considerable savings over the reference drug for the 28 European Union countries, according to a study in Advances in Therapy.
The analysis discusses how using the biosimilar CT-P10 in place of rituximab, could impact both budgets and patients’ ability to access the medicine. CT-P10, sold as Truxima, was approved this February for all indications of the reference drug, which include cancers like non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), in addition to autoimmune disorders, such as rheumatoid arthritis (RA). These 3 conditions, which account for 90% of all rituximab consumed in the study setting, were the primary focus of the new budget analysis.
Researchers estimated the proportion of patients with all diagnoses who will receive CT-P10 instead of the branded drug over a 1-year period at 30%. They also calculated the costs for both the biosimilar and the reference based on the list price and annual dose in milligrams of drug required for each diagnosis. Assuming the CT-P10 would cost 70% of what the branded drug does, the projected budget savings in Europe totaled just over €90 million in 1 year. The researchers also projected that these savings would allow 7531 additional patients to access rituximab therapy that year, or a 6.4% increase in patients taking rituximab.
Specifically, 43.3% of the savings would come from the treatment of NHL, while approximately 26.9% and 19.8% would come from treating RA and CLL, respectively. The bulk of the savings (70%) would occur in 5 European countries: Germany (22.8%), Italy (17.7%), France (13.5%), Spain (8.4%), and the United Kingdom (7.5%). Of the 7531 additional patients projected to gain access to rituximab treatment, 2857 would use it to treat RA, 2263 would use it for NHL, and 1624 would take it for CLL, while 787 would use it for a less common diagnosis or an off-label use.
The researchers then modeled potential budget savings and expanded patient access in a 3-year scenario where CT-P10’s market share would be 30% in the first year, 40% in the second, and 50% in the third. They estimated that Europe would save about €570 million in this scenario, which would allow 47,695 more patients to access treatment.
“These data clearly represent a substantial societal health gain and it can be concluded from our findings that, with some assumptions as defined in the model, use of CT-P10 will present significant savings for healthcare systems, in accordance with our stated hypothesis,” the study authors wrote.
They noted that their estimates could be on the conservative side if the price of CT-P10 is substantially lower than expected; their models assumed the biosimilar price would be 30% less costly than branded rituximab, but industry experts have said the actual difference could be twice as great.
However, the study authors acknowledged that the cost savings represent just one of the many factors that influence the uptake of biosimilars, including perceptions of the new drugs among patients, payers, and prescribers. For instance, clinicians must feel confident that CT-P10 is just as safe and effective as the branded drug for both, treatment-naïve patients and those switching from the branded drug to the biosimilar.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.